- Title
- Cytochrome P450 inhibiting/inducing medication use among patients with advanced ovarian cancer who receive or are eligible for poly (ADP-ribose) polymerase inhibitors as first line maintenance therapy (2200)
- Creators
- Dana ChaseBobbie Rimel - Cedars-Sinai Medical CenterJessica PerhanidisArmen Ghazarian - GlaxoSmithKlineElla Xiaoyan Du - Analysis GroupTravis Wang - Analysis GroupJinlin Song - Analysis GroupAmanda GolembeskyJean HurteauRitu Salani - University of California, Los AngelesBradley Monk - Creighton University
- Publication Details
- Gynecologic oncology, Vol.176, p.S257
- Identifiers
- 991006041272402656
- Academic Unit
- Obstetrics & Gynecology
- Language
- English
- Resource Type
- Journal article
Journal article
Cytochrome P450 inhibiting/inducing medication use among patients with advanced ovarian cancer who receive or are eligible for poly (ADP-ribose) polymerase inhibitors as first line maintenance therapy (2200)
Gynecologic oncology, Vol.176, p.S257
09/2023
Metrics
1 Record Views